Development of multi-epitope vaccines targeting wild-type sequence p53 peptides

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Loss of p53 tumor-suppressor function is a frequent event in human cancers.
• This dysfunction can lead to increased presentation of wild-type (wt) p53 peptides to immune cells.
• This immune presentation provides a rationale for developing wt p53 peptide-based cancer vaccines.

Purpose of the Study:

• To review preclinical evidence from murine models and other studies supporting wt p53 peptide vaccines.
• To discuss the transition of wt p53 peptide vaccines from preclinical research to clinical cancer immunotherapy.
• To illustrate the complexities and challenges in selecting wt p53 epitopes for vaccine development.

Main Methods:

• Review of preclinical data from murine tumor models.
• Analysis of preclinical studies informing clinical vaccine introduction.
• Examination of literature on wt p53 epitope selection and vaccine application.

Main Results:

• Evidence supports the use of wt p53 peptide-based vaccines in cancer immunotherapy.
• Preclinical findings have guided the clinical development of these vaccines.
• The process of wt p53 epitope selection is complex and presents challenges.

Conclusions:

• Wt p53 peptide vaccines represent a potential strategy for cancer immunotherapy.
• Clinical application requires careful consideration of epitope selection and associated challenges.
• Further research and development are needed to optimize p53-based cancer vaccines.